Stanley Jordan, MD
4 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant (NCT03380962) | Stanley Jordan, MD | 2018-02-27 |
| Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant (NCT03380377) | Stanley Jordan, MD | 2018-02-21 |
Track Stanley Jordan, MD automatically
Every clearance here is in the API, with alerts when new ones post.